ImmunoPrecise Antibodies Ltd. (IPA)

Market Cap	27.37M
Revenue (ttm)	17.67M
Net Income (ttm)	-10.64M
Shares Out	26.32M
EPS (ttm)	-0.41
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	49,352
Open	1.000
Previous Close	0.995
Day's Range	0.990 - 1.040
52-Week Range	0.940 - 3.100
Beta	0.29
Analysts	Strong Buy
Price Target	7.00 (+576.33%)
Earnings Date	Jul 9, 2024

About IPA

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In a...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 3, 2017
• Employees: 102
• Stock Exchange: NASDAQ
• Ticker Symbol: IPA

Financial Performance

In 2023, IPA's revenue was 20.67 million, an increase of 6.72% compared to the previous year's 19.36 million. Losses were -26.56 million, 59.0% more than in 2022.

Financial numbers in CAD

Analyst Forecast

According to 2 analysts, the average rating for IPA stock is "Strong Buy." The 12-month stock price forecast is $7.0, which is an increase of 576.33% from the latest price.

Price Target

$7.0

(576.33% upside)

Analyst Consensus: Strong Buy